Blood products and vaccines supplier CSL expects that settlement of an antitrust class action in the United States will reduce its fiscal 2014 net profit by $US39 million ($A41.47 million).

CSL on Monday said it had agreed to settle the law suit that was filed by various hospital groups in the US and Puerto Rico and has been going on since 2009.

The settlement, including payment of $US64 million by CSL, is subject to approval by the US federal court.

It is tax deductible in the US.

The settlement agreement dismisses claims against CSL and the Plasma Protein Therapeutics Association.

"If approved, the settlement represents a one-off charge reducing NPAT (net profit after tax) expectations for fiscal 2014 by $US39 million," CSL said in a statement to the Australian Securities Exchange.

"This charge takes anticipated NPAT growth for the current financial year to approximately seven per cent, at 2012/2013 exchange rates."

CSL chief executive Paul Perreault said CSL still rejects any allegation of wrongdoing but had negotiated a settlement to avoid the matter dragging on.

"To pursue the case further would have required several more years of management time and focus as well as substantial additional legal costs with no absolute certainty of the outcome," he said.

The lawsuit alleged that CSL and a competitor had conspired to restrict output and artificially increase the price for plasma-derived therapies in the US.

Shares in CSL were 40 cents lower at $64.64 at 1025 AEDT.


Publishing Services International Limited (PSIL) is the publisher and operator of a worldwide network of online news sites dedicated to delivering fair, accurate and relevant reporting from a variety of the world’s most trusted sources – from the biggest cities to the smallest towns.

We deliver positive and powerful messages to our readers, providing up‑to‑the‑second news that matters to the individual.

Our promise is to serve communities and individuals worldwide, delivering information that hasn’t always been available to them. We will give them back a voice – a voice that’s empowering because it is theirs – and provide a platform to communicate between themselves and the world.

We believe people are not just generic demographics; they are individuals with their own preferences and curiosities. We are about understanding these individuals, listening to them, and serving them.

We are the new pioneering spirit of news – we’re not talking to everyone, we’re talking with every one.

If you want your news, your voice, your way, on your time – we’ve got news for you.




If you have any questions or concerns please email us on


  • Australia, Toll Free 1-800-983-421
  • Hong Kong, Toll Free 800-906-187
  • Singapore, Toll Free 800-852-3871
  • USA/Canada, Toll Free 1-800-830-4132

Advertise With Us

Interested in being awesome?
Contact us by email or phone.